Eliglustat
Gaucher Disease
Peking Union Medical College HospitalSmall moleculePhase 3Active
BBB
76/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 67/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Gaucher Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Taliglucerase Alfa Protalix | Phase 4 | A |
Velaglucerase Alfa Takeda | Phase 4 | A |
Cerezyme Sanofi | Phase 4 | A |
Cerezyme Sanofi | Phase 4 | BBB |
Cerezyme® / Imiglucerase University Hospital, Clermont-Ferrand | Phase 4 | BBB |
View all 30 →
Same molecule, other indications
Eliglustat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →